Urticaria News and Research

RSS

Urticaria are itchy, raised red areas on the skin. Urticaria are caused by a reaction to certain foods, drugs, infections, or emotional stress. Also called hives.

The role of SARS-CoV-2 in COVID-19-associated chilblains

A recent study published in the British Journal of Dermatology evaluated COVID-19-associated chilblains.

23 Aug 2022

Evaluating the safety of COVID-19 vaccines in younger children

Researchers investigated the safety of COVID-19 vaccines in children in the US.

20 May 2022

Assessing the association of COVID-19 and Immunoglobulin A vasculitis in children

In a recent study posted to the Research Square* preprint server, researchers conducted a systematic review to investigate any association between immunoglobulin A (IgA) vasculitis and coronavirus disease 2019 (COVID-19) in children.

8 Feb 2022

Research reveals key differences between childhood and adult chronic spontaneous urticaria

New research presented at EADV 30th Congress today unveils key insights on the characteristic differences in chronic spontaneous urticaria in children versus adults.

3 Oct 2021

Post mRNA-1273 vaccination rashes

A group of researchers reported that skin reactions after the administration of the mRNA-1273 vaccine are rare yet possible.

30 Aug 2021

How can COVID-19 affect the skin?

A new review published in the journal Canadian Family Physician describes skin diseases caused by the coronavirus disease 2019 (COVID-19).

20 Aug 2021

FDA approves an intravenous medication to treat patients with Pompe disease

Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.

6 Aug 2021

FDA grants accelerated approval for first-of-its-kind Alzheimer's treatment

Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer's, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

7 Jun 2021

Metabolic testing of COVID-19 patients through skin imprints

There is, therefore, a great need to understand how the illness can be diagnosed using more convenient and inexpensive methods. A new study posted to the medRxiv preprint server reveals the potential role of skin imprints to test for biomarkers that indicate a diagnosis of COVID-19 in a non-invasive way.

22 Apr 2021

Chilblain-like skin lesions reported in adolescents and young adults during the pandemic

A team of investigators in the Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain and Dermatologia Pediatrica Association, Bari, Italy, say acral ischemic lesions, similar to chilblains, have been reported across the globe throughout the COVID-19 pandemic.

17 Nov 2020

Research shows some COVID-19 patients experience long-lasting skin symptoms

Some COVID-19 patients experience long-lasting skin symptoms that vary according to type of COVID-19 skin rash, a late-breaking abstract will reveal today at the 29th EADV Congress, EADV Virtual.

30 Oct 2020

Skin rash may be a symptom of COVID-19

Researchers at King’s College London and Zoe Global Ltd have conducted a study suggesting that skin rashes could be valuable predictors of coronavirus disease 2019 (COVID-19).

13 Jul 2020

New, previously unknown form of familial cold urticaria discovered

Skin rash combined with head and joint pain: these are the symptoms which patients with familial (hereditary) cold urticaria develop when exposed to temperatures below 15 °C.

27 Apr 2020

Researchers succeed in creating complex pattern of hives

Hives afflict 1 in 5 people, but the exact mechanisms behind the itchy red rashes are not well known. The research team studied the patterns of hives in patients and reproduced the hive patterns using a mathematical model called a reaction-diffusion model, a common prototype for understanding how patterns develop. The researchers' model is a single equation type which had never before been used to generate complex patterns.

28 Jan 2020

Meta-analysis reveals effective treatment options for urticarial vasculitis

What treatments are available for patients with the rare inflammatory disease known as urticarial vasculitis? How effective are these treatments? Researchers from Charité - Universitätsmedizin Berlin embarked on a systematic review and meta-analysis to address these questions.

30 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Leadiant Biosciences announces FDA approval of Revcovi for treating pediatric, adult ADA-SCID patients

Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.

7 Oct 2018

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved AJOVY injection for the preventive treatment of migraine in adults.

17 Sep 2018

New approach to cultivate hypoallergenic tomato and strawberry varieties

The incidence of food allergies has increased in recent decades: It affects three to four percent of the adult population and five percent of children.

16 Jul 2018

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).

28 Apr 2018